MedTrace Logo

Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents

NCT03894696 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-07-08

No results posted yet for this study

Summary

The primary objective of this study is to prospectively analyse psychiatric outcomes, specifically depression and anxiety in patients with hepatitis C virus infection who are initiated on DAA therapy (sofosbuvir based regimen).

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

Direct Acting Antivirals

follow up chronic HCV patients recieving DAAs to detect anxiety and depression

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-04-01
Completion
2020-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894696 on ClinicalTrials.gov